Literature DB >> 34250408

Exceptional Response to Trastuzumab in a Heavily Pretreated Patient With ERBB3-Mutated Metastatic Breast Cancer.

Swapnil Parmar1, Jamie M Keck1,2, Ben Kong1, Regan Look3, Brett Johnson1,2,4, Janice Patterson1, Marilyne Labrie1,5, Alexander R Guimaraes1,5,6, Christopher L Corless1,7, Carol Beadling1, Annette Kolodzie1,2, Raymond Bergan1, Joe W Gray1,2,4, Gordon B Mills1,5,8, Zahi I Mitri1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34250408      PMCID: PMC8232752          DOI: 10.1200/PO.20.00183

Source DB:  PubMed          Journal:  JCO Precis Oncol        ISSN: 2473-4284


× No keyword cloud information.
  19 in total

Review 1.  The ErbB signaling network: receptor heterodimerization in development and cancer.

Authors:  M A Olayioye; R M Neve; H A Lane; N E Hynes
Journal:  EMBO J       Date:  2000-07-03       Impact factor: 11.598

Review 2.  Mutational analysis of breast cancer: guiding personalized treatments.

Authors:  Matthew J Ellis
Journal:  Breast       Date:  2013-08       Impact factor: 4.380

3.  The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation.

Authors:  Thomas Holbro; Roger R Beerli; Francisca Maurer; Magdalena Koziczak; Carlos F Barbas; Nancy E Hynes
Journal:  Proc Natl Acad Sci U S A       Date:  2003-07-09       Impact factor: 11.205

4.  Oncogenic ERBB3 mutations in human cancers.

Authors:  Bijay S Jaiswal; Noelyn M Kljavin; Eric W Stawiski; Emily Chan; Chaitali Parikh; Steffen Durinck; Subhra Chaudhuri; Kanan Pujara; Joseph Guillory; Kyle A Edgar; Vasantharajan Janakiraman; Rolf-Peter Scholz; Krista K Bowman; Maria Lorenzo; Hong Li; Jiansheng Wu; Wenlin Yuan; Brock A Peters; Zhengyan Kan; Jeremy Stinson; Michelle Mak; Zora Modrusan; Charles Eigenbrot; Ron Firestein; Howard M Stern; Krishnaraj Rajalingam; Gabriele Schaefer; Mark A Merchant; Mark X Sliwkowski; Frederic J de Sauvage; Somasekar Seshagiri
Journal:  Cancer Cell       Date:  2013-05-13       Impact factor: 31.743

5.  HER2 Amplification in Tumors Activates PI3K/Akt Signaling Independent of HER3.

Authors:  Ana Ruiz-Saenz; Courtney Dreyer; Marcia R Campbell; Veronica Steri; Nate Gulizia; Mark M Moasser
Journal:  Cancer Res       Date:  2018-05-14       Impact factor: 12.701

6.  The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data.

Authors:  Ethan Cerami; Jianjiong Gao; Ugur Dogrusoz; Benjamin E Gross; Selcuk Onur Sumer; Bülent Arman Aksoy; Anders Jacobsen; Caitlin J Byrne; Michael L Heuer; Erik Larsson; Yevgeniy Antipin; Boris Reva; Arthur P Goldberg; Chris Sander; Nikolaus Schultz
Journal:  Cancer Discov       Date:  2012-05       Impact factor: 39.397

Review 7.  ERBB3 mutations in cancer: biological aspects, prevalence and therapeutics.

Authors:  Nicolas Kiavue; Luc Cabel; Samia Melaabi; Guillaume Bataillon; Celine Callens; Florence Lerebours; Jean-Yves Pierga; Francois-Clement Bidard
Journal:  Oncogene       Date:  2019-09-13       Impact factor: 9.867

8.  The somatic mutation profiles of 2,433 breast cancers refines their genomic and transcriptomic landscapes.

Authors:  Bernard Pereira; Suet-Feung Chin; Oscar M Rueda; Hans-Kristian Moen Vollan; Elena Provenzano; Helen A Bardwell; Michelle Pugh; Linda Jones; Roslin Russell; Stephen-John Sammut; Dana W Y Tsui; Bin Liu; Sarah-Jane Dawson; Jean Abraham; Helen Northen; John F Peden; Abhik Mukherjee; Gulisa Turashvili; Andrew R Green; Steve McKinney; Arusha Oloumi; Sohrab Shah; Nitzan Rosenfeld; Leigh Murphy; David R Bentley; Ian O Ellis; Arnie Purushotham; Sarah E Pinder; Anne-Lise Børresen-Dale; Helena M Earl; Paul D Pharoah; Mark T Ross; Samuel Aparicio; Carlos Caldas
Journal:  Nat Commun       Date:  2016-05-10       Impact factor: 14.919

9.  Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients.

Authors:  Ahmet Zehir; Ryma Benayed; Ronak H Shah; Aijazuddin Syed; Sumit Middha; Hyunjae R Kim; Preethi Srinivasan; Jianjiong Gao; Debyani Chakravarty; Sean M Devlin; Matthew D Hellmann; David A Barron; Alison M Schram; Meera Hameed; Snjezana Dogan; Dara S Ross; Jaclyn F Hechtman; Deborah F DeLair; JinJuan Yao; Diana L Mandelker; Donavan T Cheng; Raghu Chandramohan; Abhinita S Mohanty; Ryan N Ptashkin; Gowtham Jayakumaran; Meera Prasad; Mustafa H Syed; Anoop Balakrishnan Rema; Zhen Y Liu; Khedoudja Nafa; Laetitia Borsu; Justyna Sadowska; Jacklyn Casanova; Ruben Bacares; Iwona J Kiecka; Anna Razumova; Julie B Son; Lisa Stewart; Tessara Baldi; Kerry A Mullaney; Hikmat Al-Ahmadie; Efsevia Vakiani; Adam A Abeshouse; Alexander V Penson; Philip Jonsson; Niedzica Camacho; Matthew T Chang; Helen H Won; Benjamin E Gross; Ritika Kundra; Zachary J Heins; Hsiao-Wei Chen; Sarah Phillips; Hongxin Zhang; Jiaojiao Wang; Angelica Ochoa; Jonathan Wills; Michael Eubank; Stacy B Thomas; Stuart M Gardos; Dalicia N Reales; Jesse Galle; Robert Durany; Roy Cambria; Wassim Abida; Andrea Cercek; Darren R Feldman; Mrinal M Gounder; A Ari Hakimi; James J Harding; Gopa Iyer; Yelena Y Janjigian; Emmet J Jordan; Ciara M Kelly; Maeve A Lowery; Luc G T Morris; Antonio M Omuro; Nitya Raj; Pedram Razavi; Alexander N Shoushtari; Neerav Shukla; Tara E Soumerai; Anna M Varghese; Rona Yaeger; Jonathan Coleman; Bernard Bochner; Gregory J Riely; Leonard B Saltz; Howard I Scher; Paul J Sabbatini; Mark E Robson; David S Klimstra; Barry S Taylor; Jose Baselga; Nikolaus Schultz; David M Hyman; Maria E Arcila; David B Solit; Marc Ladanyi; Michael F Berger
Journal:  Nat Med       Date:  2017-05-08       Impact factor: 53.440

10.  Implementing a comprehensive translational oncology platform: from molecular testing to actionability.

Authors:  Zahi I Mitri; Swapnil Parmar; Brett Johnson; Annette Kolodzie; Jamie M Keck; Max Morris; Alexander R Guimaraes; Brooke R Beckett; Uma Borate; Charles D Lopez; Kathleen A Kemmer; Joshi J Alumkal; Tomasz M Beer; Christopher L Corless; Gordon B Mills; Joe W Gray; Raymond C Bergan
Journal:  J Transl Med       Date:  2018-12-14       Impact factor: 5.531

View more
  1 in total

1.  The Human Tumor Atlas Network's beginning steps toward the future of collaborative multi-omic discovery.

Authors:  David B Page
Journal:  Cell Rep Med       Date:  2022-02-15
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.